PL3180356T3 - Ludzkie przeciwciało anty-fgfr4 - Google Patents

Ludzkie przeciwciało anty-fgfr4

Info

Publication number: PL3180356T3
Authority: PL; Poland
Prior art keywords: human anti; fgfr4 antibody; fgfr4; antibody; human
Prior art date: 2014-08-11

Application number

PL15748050T

Other languages

English (en)

Inventor

Reimar Abraham

Keisuke Fukuchi

Tanja LANGE

Johannes Bange

Ichiro Watanabe

Shinko HAYASHI

Toshiaki Ohtsuka

Original Assignee

Daiichi Sankyo Europe Gmbh

Daiichi Sankyo Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-11

Filing date

2015-08-11

Publication date

2020-04-30

2015-08-11 Application filed by Daiichi Sankyo Europe Gmbh, Daiichi Sankyo Co., Ltd. filed Critical Daiichi Sankyo Europe Gmbh

2020-04-30 Publication of PL3180356T3 publication Critical patent/PL3180356T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

PL15748050T 2014-08-11 2015-08-11 Ludzkie przeciwciało anty-fgfr4 PL3180356T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14180555		2014-08-11
PCT/EP2015/068440 WO2016023894A1 (en)	2014-08-11	2015-08-11	Human anti-fgfr4 antibody
EP15748050.0A EP3180356B1 (en)	2014-08-11	2015-08-11	Human anti-fgfr4 antibody

Publications (1)

Publication Number	Publication Date
PL3180356T3 true PL3180356T3 (pl)	2020-04-30

Family

ID=51300622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15748050T PL3180356T3 (pl)	2014-08-11	2015-08-11	Ludzkie przeciwciało anty-fgfr4

Country Status (7)

Country	Link
US (1)	US10358498B2 (pl)
EP (1)	EP3180356B1 (pl)
JP (2)	JP7011939B2 (pl)
ES (1)	ES2764418T3 (pl)
PL (1)	PL3180356T3 (pl)
TW (1)	TWI710575B (pl)
WO (1)	WO2016023894A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2277892A3 (en)	1998-12-08	2011-04-27	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
EP3095465A1 (en)	2015-05-19	2016-11-23	U3 Pharma GmbH	Combination of fgfr4-inhibitor and bile acid sequestrant
JP6909220B2 (ja)	2016-02-10	2021-07-28	ダイイチサンキョウヨーロッパゲーエムベーハー	ヒト抗ｆｇｆｒ４抗体およびソラフェニブの組み合わせ
WO2018055503A1 (en)	2016-09-20	2018-03-29	Novartis Ag	Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
AU2017354082B2 (en)	2016-11-02	2023-07-27	Novartis Ag	Combinations of FGFR4 inhibitors and bile acid sequestrants
EP3444275A1 (en) *	2017-08-16	2019-02-20	Exiris S.r.l.	Monoclonal antibody anti-fgfr4
CA3084969A1 (en) *	2017-12-08	2019-06-13	Hiroyuki Miyoshi	Method of preparing cancer spheroid and method of selecting colorectal cancer patient
CN111471109B (zh) *	2020-04-08	2021-07-23	中国科学院深圳先进技术研究院	一种抗成纤维细胞生长因子受体4单克隆抗体及其制备方法和用途
EP4509142A1 (en)	2023-08-16	2025-02-19	Ona Therapeutics S.L.	Fgfr4 as target in cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2933702A1 (fr) *	2008-07-08	2010-01-15	Sanofi Aventis	Antagonistes specifiques du recepteur fgf-r4
BR112013024717A2 (pt) *	2011-04-07	2017-08-08	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo

2015
- 2015-08-11 EP EP15748050.0A patent/EP3180356B1/en active Active
- 2015-08-11 US US15/503,095 patent/US10358498B2/en active Active
- 2015-08-11 WO PCT/EP2015/068440 patent/WO2016023894A1/en active Application Filing
- 2015-08-11 JP JP2017508103A patent/JP7011939B2/ja active Active
- 2015-08-11 ES ES15748050T patent/ES2764418T3/es active Active
- 2015-08-11 TW TW104126103A patent/TWI710575B/zh active
- 2015-08-11 PL PL15748050T patent/PL3180356T3/pl unknown
2020
- 2020-07-17 JP JP2020122564A patent/JP2020183418A/ja active Pending

Also Published As

Publication number	Publication date
EP3180356A1 (en)	2017-06-21
ES2764418T3 (es)	2020-06-03
US20170226213A1 (en)	2017-08-10
WO2016023894A1 (en)	2016-02-18
TW201619198A (zh)	2016-06-01
US10358498B2 (en)	2019-07-23
TWI710575B (zh)	2020-11-21
JP2020183418A (ja)	2020-11-12
JP7011939B2 (ja)	2022-01-27
EP3180356B1 (en)	2019-11-27
JP2017526671A (ja)	2017-09-14

Publication	Publication Date	Title
IL252004B (en)	2022-10-01	Ether-substituted antibody
IL250583A0 (en)	2017-04-30	Anti-tigit antibodies
SG11201703403TA (en)	2017-05-30	Anti-tim-3 antibodies
SG11201703346PA (en)	2017-05-30	Anti-tim-3 antibodies
GB201411320D0 (en)	2014-08-06	Antibody construct
IL252422B (en)	2018-06-28	Effector-deficient anti-cd32a antibodies
IL291164A (en)	2022-05-01	Anti-nme antibody
PT3101132T (pt)	2021-12-31	Anticorpo humano anti-transtirretina
ZA201701461B (en)	2022-07-27	Antibody formulations
IL246603A0 (en)	2016-08-31	A new antibody against netrin-1
PL3180356T3 (pl)	2020-04-30	Ludzkie przeciwciało anty-fgfr4
IL250374B (en)	2021-04-29	Antibodies against ceramide
GB201410520D0 (en)	2014-07-30	Antibody
SG11201700922YA (en)	2017-03-30	Anti-orai1 antibody
IL247988A0 (en)	2016-11-30	Antibodies against hpa–1a
GB201418776D0 (en)	2014-12-03	Antibody
GB201413745D0 (en)	2014-09-17	Antibody
GB201411319D0 (en)	2014-08-06	Antibody
GB201407535D0 (en)	2014-06-11	Antibody Drug - Conjugates
GB201419092D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201419089D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201417614D0 (en)	2014-11-19	Antibodies
GB201414270D0 (en)	2014-09-24	Antibodies
GB201405775D0 (en)	2014-05-14	Antibodies
GB201415526D0 (en)	2014-10-15	Antibody Formulations